811 material Form 8-K filings that 685 companies we cover made with the SEC in April 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Jazz Pharmaceuticals Ireland Limited agreed on April 7, 2025 to a preliminary class settlement with indirect Xyrem purchasers, paying $145 million in a lump sum from cash on hand. The company expects a pre-tax charge of about $145 million in the first quarter of 2025, and the deal remains subject to court approval. Shareholders face a known cash cost and a charge, and the company warns that further settlements with other plaintiffs may add significant charges.
Lump-sum payment of $145 million, funded with cash on hand
Expected pre-tax charge of approximately $145 million in the first quarter of 2025
Settlement requires Court approval and can be rescinded if a specified percentage of potential class members opt out
Company may enter additional settlements with remaining plaintiffs, which could be significant; the company denies wrongdoing
For the quarter ended March 1, 2025, Cal-Maine reported net sales of $1.4 billion, up from $703.1 million a year earlier, as average selling prices rose amid tight egg supply from avian influenza. The company also signed a definitive agreement to acquire Echo Lake Foods for approximately $258 million in cash, with closing expected by the end of fiscal 2025. Higher profit and the planned acquisition are the main items for shareholders.
Net income attributable to Cal-Maine was $508.5 million, or $10.38 per diluted share, versus $146.7 million, or $3.00 per diluted share, a year earlier.
Net average selling price was $4.060 per dozen, compared with $2.247 a year earlier.
Echo Lake Foods acquisition for approximately $258 million, excluding expected tax assets, to be funded with cash on hand; closing expected by end of fiscal 2025.
Cash dividend of approximately $3.46 per share, payable May 15, 2025 to holders of record on April 30, 2025; no shares were repurchased under the $500 million program in the quarter.
WD-40 reported fiscal second-quarter 2025 net sales of $146.1 million, up 5% from a year earlier, and net income of $29.9 million, up 92%. Net income included an $11.9 million one-time tax benefit from releasing an uncertain tax position; excluding it, net income rose $2.4 million, or 15%. The company raised its fiscal 2025 gross margin and diluted EPS guidance, which shareholders will weigh alongside the one-time tax benefit in reported profit.
Q2 net sales were $146.1 million, up 5%; maintenance product sales were $139.3 million, up 6%.
Diluted EPS was $2.19 versus $1.14; non-GAAP adjusted diluted EPS was $1.32, up 16%, excluding the $0.87 tax benefit effect.
Fiscal 2025 gross margin guidance raised to 55% to 56%; diluted EPS guidance raised to $5.25 to $5.55.
Operating income guidance of $95 million to $100 million was unchanged; net sales guidance of $600 million to $630 million was also projected.
CVS Health appointed Brian O. Newman, former CFO of United Parcel Service, as executive vice president and chief financial officer effective May 12, 2025, replacing Thomas F. Cowhey, who becomes a strategic advisor to the CEO. The company also named Amy L. Compton-Phillips, M.D. as chief medical officer effective May 19, 2025. The filing also says the company currently expects 2025 results to meet or exceed prior guidance, based on year-to-date results through February, while first-quarter closing procedures are not yet complete.
Brian O. Newman becomes CFO effective May 12, 2025, and is CFO designate from April 21, 2025; he will receive a $1.0 million annualized base salary and a $7.0 million target annual equity award
Thomas F. Cowhey ceases to be CFO on May 12, 2025, and will remain as Strategic Advisor to the President and CEO until a departure date not yet determined
Amy L. Compton-Phillips, M.D. becomes executive vice president and chief medical officer effective May 19, 2025
Company expects 2025 financial results will meet or exceed previously issued guidance, but first-quarter 2025 financial closing is not yet complete and results may change
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.